Ovoca Bio (LSE:OVB) Cash-to-Debt : No Debt ⁽¹⁾ (As of Jun. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Ovoca Bio Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Ovoca Bio's cash to debt ratio for the quarter that ended in Jun. 2024 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Ovoca Bio could pay off its debt using the cash in hand for the quarter that ended in Jun. 2024.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Ovoca Bio's Cash-to-Debt or its related term are showing as below:

LSE:OVB' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.84 Med: No Debt Max: No Debt
Current: No Debt

During the past 13 years, Ovoca Bio's highest Cash to Debt Ratio was No Debt. The lowest was 1.84. And the median was No Debt.

LSE:OVB's Cash-to-Debt is ranked better than
99.87% of 1487 companies
in the Biotechnology industry
Industry Median: 6.38 vs LSE:OVB: No Debt

Ovoca Bio Cash-to-Debt Historical Data

The historical data trend for Ovoca Bio's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Ovoca Bio Cash-to-Debt Chart

Ovoca Bio Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

Ovoca Bio Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Ovoca Bio's Cash-to-Debt

For the Biotechnology subindustry, Ovoca Bio's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ovoca Bio's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ovoca Bio's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Ovoca Bio's Cash-to-Debt falls into.

Ovoca Bio Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Ovoca Bio's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Ovoca Bio had no debt ⁽¹⁾.

Ovoca Bio's Cash to Debt Ratio for the quarter that ended in Jun. 2024 is calculated as:

Ovoca Bio had no debt ⁽¹⁾.

Ovoca Bio (LSE:OVB) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Ovoca Bio Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Ovoca Bio's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Ovoca Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ovoca Bio PLC (LSE:OVB) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

OVXA:Ireland OVB.GB:UK OVXA:Germany

Address

17 Pembroke Street Upper, Dublin, IRL, D02 AT22

Website

https://www.ovocabio.com

Ovoca Bio PLC is a life science investment company. The company is engaged in investing in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. The group has two business segments, bio-pharmaceutical and investment, which are operated principally in Russian Federation and investment activities operated from Bermuda, and with administrative activities in the Republic of Ireland. Its product candidate includes IVIX - Libicore - a novel synthetic peptide, administrated through a nasal spray.